Personalized lifestyle program for heart and metabolic health in adults with obesity
Tests a personalized lifestyle program in Emirati adults with obesity.
Plain-language title generated from the registry record
Registry title: Precision Lifestyle Medicine Program for IFHAS Participants
Key facts
- Where
- Abu Dhabi, United Arab EmiratesSee the site
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 25 and 50 years old?
Source: NCT07742917, who can take part
Where in United Arab Emirates
- Institute for Healthier LivingAbu Dhabi, United Arab EmiratesTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Institute for Healthier Living Abu Dhabi
- Trial code
- NCT07742917
- Record updated
- 3 August 2026
- Original description
The goal of this clinical trial is to evaluate whether a precision lifestyle medicine intervention can improve cardiometabolic health in Emirati adults aged 25 to 50 years living in Abu Dhabi with obesity (BMI 30-35 kg/m²) who have previously completed IFHAS screening. The study will also use IFHAS screening data to better understand participants' health profiles and the relationship between lifestyle factors and chronic diseases. The main questions it aims to answer are:Read full original descriptionShow less
Application of a Precision Lifestyle Medicine Clinical Program for a Sample of IFHAS Screening Cohort
The goal of this clinical trial is to evaluate whether a precision lifestyle medicine intervention can improve cardiometabolic health in Emirati adults aged 25 to 50 years living in Abu Dhabi with obesity (BMI 30-35 kg/m²) who have previously completed IFHAS screening. The study will also use IFHAS screening data to better understand participants' health profiles and the relationship between lifestyle factors and chronic diseases. The main questions it aims to answer are:
* Does a precision lifestyle medicine program improve cardiometabolic biomarkers after an 18-week intervention? * Can IFHAS screening data be used to identify health risk profiles and support personalized lifestyle interventions for the Emirati population?
Researchers will compare participants receiving the precision lifestyle medicine intervention with a propensity-matched control group receiving standard IFHAS care to determine whether the intervention leads to greater improvements in cardiometabolic health.
Participants will:
* Take part in an 18-week personalized lifestyle medicine program tailored to their health profile. * Attend study visits and complete health assessments over a total study period of 24 weeks. * Undergo cardiometabolic biomarker assessments before and after the intervention. * Complete questionnaires or assessments about their adherence to the lifestyle program and their experience with the precision lifestyle medicine clinic. * Provide biological samples to support the establishment of a biomarker repository for future research.
Inclusion: Emiratis residing in Abu Dhabi emirate; Aged 25-50 years; BMI 30-35 kg/m²; Thiqa cardholder; Previous participation in IFHAS screening; Able to provide informed consent; Participant in the Emirati Genome Programme; No weight-loss medications (e.g., Ozempic, Saxenda, Wegovy) within 3 months of enrollment.
Exclusion: Taking weight loss medication such as GLP-1 drugs (Ozempic, Saxenda, Wegovy); Transplant surgery within 12 months; Surgery within 3 months prior to recruitment; Active treatment for serious medical conditions (cancer, planned surgery, immunomodulation); Active psychiatric conditions, cognitive impairment, or mental health conditions affecting study participation; Aged under 25 years or over 50 years of age; BMI range under 30 kg/m2 and over 35 kg/m2; Pregnancy; Physical limitations preventing exercise participation; Current enrolment in other lifestyle intervention programs; Contraindication to MRI or DEXA imaging, including severe claustrophobia or need for sedation.